Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.

NCT01899079 is registered in ClinicalTrials.gov with NanoString Technologies, Inc. as lead sponsor.

NCT NCT01899079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01899079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.
Lead sponsor
NanoString Technologies, Inc.
Phase
Observational
Overall status
Completed
Start date
June 30, 2013
Completion date
July 31, 2014
Enrollment
217 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer